Filing search / Lineage Cell Therapeutics, Inc. / "Executive Compensation"

424B5

LCTX Lineage Cell Therapeutics, Inc.

14 May 24

Prospectus supplement for primary offering

4:36pm

) scaled executive compensation disclosure requirements; and (iii) providing only two years of audited financial statements, instead of three years. We … ) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act of 2002; (ii) scaled executive

424B5

LCTX Lineage Cell Therapeutics, Inc.

22 Mar 24

Prospectus supplement for primary offering

4:32pm

required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act of 2002; (ii) scaled executive compensation disclosure

8-K

tv5rg5o6dtp08

7 Sep 23

Departure of Directors or Certain Officers

5:01pm